Therefore, our findings reveal a druggable CAST–Drp1 signaling axis in the pathogenesis of HD and suggest that a CHIR99021-like small molecule might be a useful lead in the development of HD therapy. The gene discussed is DNM1L; the disease is Huntington disease.